IBIO-600 / iBio, AstralBio - LARVOL DELTA

Preclinical Evaluation of a Long-Acting Anti-Myostatin Therapy for Obesity (OBESITY WEEK 2025) - "These preclinical findings highlight the potential of IBIO-600 as a differentiated therapeutic for obesity, offering robust muscle preservation and enabling high quality weight loss. Its extended half-life may enable infrequent dosing, and its consistent effects across models support further clinical development."

Preclinical • Genetic Disorders • Obesity

iBio Announces Proposed Public Offering (GlobeNewswire) - "iBio intends to use the net proceeds received from the offering to advance its preclinical cardiometabolic programs, including IBIO-610, the myostatin and activin A bispecific, and IBIO-600 programs, through key development milestones, as well as to continue to progress its other preclinical pipeline assets, and the balance, if any, to fund iBio’s working capital requirements and for other general corporate purposes."

Financing • Obesity

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline (GlobeNewswire) - "Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days; Additional interim in vivo data for a first-in-class Activin E antibody shows muscle sparing weight loss alone and in combination with a GLP-1 receptor agonist; It is truly remarkable we’ve been able to advance this potentially best-in-class long-acting anti-myostatin antibody to clinical candidate selection in under a year and remain fully on track for a regulatory submission in Q1 2026."

New trial • Preclinical • Obesity